scholarly journals Safety of Intravenous Autologous Bone Marrow-Derived Mesenchymal Cell Transplantation in 5 Patients With Reduced Left Ventricular Ejection Fraction

2021 ◽  
Vol 3 (9) ◽  
pp. 550-554
Author(s):  
Yukihito Sato ◽  
Takashi Kuragaichi ◽  
Shunsuke Saga ◽  
Hiroyuki Nakayama ◽  
Tomoe Obata ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Left Ventricular Ejection Fraction ◽  
Ejection Fraction ◽  
Cell Transplantation ◽  
Autologous Bone Marrow ◽  
Mesenchymal Cell ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Autologous Bone

Transplantation efficacy of autologous bone marrow mesenchymal stem cells combined with atorvastatin for acute myocardial infarction (TEAM-AMI): rationale and design of a randomized, double-blind, placebo-controlled, multi-center, Phase II TEAM-AMI trial

2019 ◽  
Vol 14 (12) ◽  
pp. 1077-1087
Author(s):  
Jun-Yan Xu ◽  
Hai-Yan Qian ◽  
Pei-Sen Huang ◽  
Jun Xu ◽  
Yu-Yan Xiong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Autologous Bone Marrow ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Marrow Mesenchymal Stem Cells ◽  
Autologous Bone

Aim: To determine the efficacy and safety of intracoronary infusion of autologous bone marrow mesenchymal stem cells (MSCINJ) in combination with intensive atorvastatin (ATV) treatment for patients with anterior ST-segment elevation myocardial infarction-elevation myocardial infarction. Patients & methods: The trial enrolls a total of 100 patients with anterior ST-elevation myocardial infarction. The subjects are randomly assigned (1:1:1:1) to receive routine ATV (20 mg/d) with placebo or MSCsINJ and intensive ATV (80 mg/d) with placebo or MSCsINJ. The primary end point is the absolute change of left ventricular ejection fraction within 12 months. The secondary end points include parameters in cardiac function, remodeling and regeneration, quality of life, biomarkers and clinical outcomes. Results & conclusion: The trial will implicate the essential of cardiac micro-environment improvement (‘fertilizing’) for cell-based therapy. Clinical Trial Registration: NCT03047772.

Sign in / Sign up

Export Citation Format

Share Document